Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Antifibrotic agents have been widely used in patients with idiopathic pulmonary fibrosis (IPF). Long-term continuation of antifibrotic therapy is required for IPF treatment to prevent disease progression. However, antifibrotic treatment has considerable adverse events, and the continuation of treatm...

Full description

Bibliographic Details
Main Authors: Kazutaka Takehara, Yasuhiko Koga, Yoshimasa Hachisu, Mitsuyoshi Utsugi, Yuri Sawada, Yasuyuki Saito, Seishi Yoshimi, Masakiyo Yatomi, Yuki Shin, Ikuo Wakamatsu, Kazue Umetsu, Shunichi Kouno, Junichi Nakagawa, Noriaki Sunaga, Toshitaka Maeno, Takeshi Hisada
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cells
Subjects:
idiopathic pulmonary fibrosis
pirfenidone
nintedanib
discontinuation
body mass index
adverse event
Online Access:https://www.mdpi.com/2073-4409/11/1/143

Internet

https://www.mdpi.com/2073-4409/11/1/143

Similar Items